CONCLUSIONS
Sarcopenia has been shown to be a risk factor for the development of
post-surgical complications in patients with hepatoblastoma. It also
seems to have a negative impact on survival. Measurement of tPMA at
baseline cross-sectional imaging as a predictor of the sarcopenia status
should be considered as part of the initial study in children with
hepatoblastoma. When detected, treatment of the sarcopenia should be a
key point in children with hepatoblastoma.